TRPC6 Inhibitory Compounds for Sepsis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bacterial or fungal severe sepsis and septic shock are ineffective, particularly for fungal infections, as regular antibiotics do not provide adequate solutions, leading to increased vascular permeability and organ failure.
Innovation Solution
A pharmaceutical composition comprising specific compounds of formula (I), which are administered to patients to treat systemic inflammatory responses, including severe sepsis and septic shock, by reducing vascular leakage and improving organ function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If regular antibiotics are used for fungal infections, then the treatment approach is simple and familiar, but the treatment is ineffective as antibiotics do not work against fungal pathogens
Solution Approach 1:
The patent develops TRPC6 inhibitor compounds that serve as a universal treatment mechanism for both bacterial and fungal sepsis. The compounds block the TRPC6 calcium channel, which is upregulated in response to both bacterial and fungal infections, thereby providing broad-spectrum effectiveness against diverse pathogens that cause sepsis and septic shock
2Reliability
If conventional sepsis treatments are used, then the treatment protocol is established, but the treatments fail to address the underlying mechanism of increased vascular permeability and organ failure
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism driving sepsis pathology - the TRPC6 calcium channel. By isolating this key pathway responsible for increased vascular permeability and organ dysfunction, the invention provides a focused therapeutic approach that directly addresses the root cause of sepsis-related mortality without requiring complex multi-target regimens
3Reliability
If no specific antifungal treatment is used, then the treatment regimen remains simple, but fungal infections progress to severe sepsis and septic shock with high mortality
Solution Approach 1:
The patent employs structure-activity relationship optimization to modify the chemical parameters of TRPC6 inhibitor compounds. By systematically varying molecular structures (as shown in the claimed formulae with different R groups) and evaluating their inhibitory potency, the invention develops optimized compounds that effectively treat fungal sepsis while maintaining manageable development complexity
Data Source
AI summary
The present invention relates to compounds of formula (I)for use in methods for of a patient with a disorder associated with bacterial or fungal severe sepsis, and bacterial or fungal septic shock and conditions arising therefrom, wherein the groups Y, A and R1 to R7 are as defined herein, pharmaceutical compositions which contain compounds of this kind and their use as medicaments for the treatment of bacterial or fungal severe sepsis and bacterial or fungal septic shock and conditions arising therefrom.